The smart solution for preclinical development

Depend on Noble Life Sciences as your partner for high-quality drug discovery & development services.

Contact Us Today »

MRSA Peritonitis-Sepsis Mouse Model  

Service Description 

Noble Life Sciences, in collaboration with ImQuest Biosciences, has optimized the peritonitis-sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). The model’s popularity derives from its ease of use with small and inexpensive animals, short-duration experiments with reproducible infections, and simple end-points.

The mouse peritonitis-sepsis model, the first animal model for antibiotic research, was used to demonstrate the efficacy of sulphonamides against Streptococcus pyogenes in 1935.

Two models are commonly used as in vivo screens for new antibacterial agents:  the neutropenic thigh model and the peritonitis-sepsis model. Noble also has an optimized mouse neutropenic thigh model. 


The mouse peritonitis-sepsis model is an important early screening method to study in vivo effects of antibacterial compounds and provides a natural step in testing of antibiotics in vivo before moving to larger animals or humans. 

MRSA Table 1

Survival of mice infected with various doses of MRSA was monitored (see figure at right). 

Survival was dose dependent.  All mice which received only the vehicle survived for 7 days. 100% of the mice that received 4 E6 CFU survived for at least 5 days whereas only about 40% of the mice that received 2 E7 CFU sur­vived in this same time period.

Higher doses produced 100% lethality within 24 hours.




MRSA Table 2

Blood samples were collected from mice at various time points post inoculation.  Bacterial counts determined by dilution and plating. 

Results of analysis of blood samples taken at 2 hours post infection are shown in the figure at right.  The concentration of bacteria in the blood correlates with the bacterial dose.